SCHEMBL844899

SCHEMBL844899

CC(C)(C)CC(=O)N1CCC[C@H]1C(=O)Nc1ccc(/C=C/c2ccc(NC(=O)[C@@H]3CCCN3C(=O)CC(C)(C)C)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.52
ALDH1A1 P00352 3/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
EP300 Q09472 1/20 0.47
CREBBP Q92793 1/20 0.47
PABPC1 P11940 1/20 0.46
HTT P42858 2/20 0.46
MAPK1 P28482 2/20 0.46
RHOC P08134 1/20 0.44
RHOA P61586 1/20 0.44
GAA P10253 1/20 0.44
KDM4E B2RXH2 1/20 0.44
LMNA P02545 1/20 0.44
TSHR P16473 1/20 0.43
F2 P00734 1/20 0.43
PRSS1 P07477 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL845251 0.88 PABPC1 (0.50) NPC1ALDH1A1CYP2C9CYP2C19MEN1
SCHEMBL845228 0.86 HCRTR1 (0.49) NPC1ALDH1A1CYP2C9CYP2C19MEN1
SCHEMBL844919 0.85 NPC1 (0.54) NPC1ALDH1A1CYP2C9CYP2C19MEN1
SCHEMBL845206 0.85 CYP2C9 (0.52) NPC1ALDH1A1CYP2C9CYP2C19KMT2A
SCHEMBL845245 0.85 PTPN1 (0.50) NPC1ALDH1A1CYP2C9CYP2C19MEN1
SCHEMBL844902 0.85 ALDH1A1 (0.47) NPC1ALDH1A1CYP2C9CYP2C19MEN1
SCHEMBL845519 0.84 ALDH1A1 (0.46) NPC1ALDH1A1CYP2C9CYP2C19MEN1
SCHEMBL845521 0.83 ALDH1A1 (0.47) NPC1ALDH1A1CYP2C9CYP2C19MEN1
SCHEMBL10299164 0.82 NPC1 (0.76) NPC1ALDH1A1CYP2C9CYP2C19MEN1
SCHEMBL10281278 0.82 NPC1 (0.76) NPC1ALDH1A1CYP2C9CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143288-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-27 US disclosed